Quetiapine Addition to Serotonin Reuptake Inhibitor Treatment in Patients With Treatment-Refractory Obsessive-Compulsive Disorder: An Open-Label Study
J Clin Psychiatry 2002;63(8):700-703
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Although patients with
obsessive-compulsive disorder (OCD) benefit from
treatment with serotonin reuptake inhibitors (SRIs), it is
estimated that 40% to 60% of the patients remain
unimproved. The objective of this study was to
examine whether addition of the atypical
antipsychotic quetiapine to SRIs is useful for patients with
OCD who do not respond to SRI monotherapy.
Method: Ten patients with OCD (DSM-IV
criteria) who had not responded to at least 3
previous treatments with an SRI at maximum dose and
duration were assigned to receive quetiapine in
addition to an SRI for 8 weeks. Treatment response was assessed using the Yale-Brown
Obsessive-Compulsive Scale (YBOCS).
Results: Seven of 10 patients responded to
the quetiapine addition. The mean±SD baseline YBOCS score of 31.4±7.8 dropped to a mean
of 20.8±8.4 at endpoint with a mean reduction
Conclusion: This is the first study to show
that treatment-refractory OCD patients may benefit from addition of quetiapine to ongoing